Outcome of AML/MDS patients (n = 81)
| . | Day 100 . | 1 year . | 3 years . | 5 years . | P . |
|---|---|---|---|---|---|
| Overall survival | 81.5 (73.0-89.9) | 54.3 (43.5-65.2) | 46.5 (35.5-57.4) | 44.8 (33.7-55.8) | |
| Disease stage at HSCT | |||||
| Early | 82.4 (64.2-100.0) | 52.9 (29.2-76.7) | 52.9 (29.2-76.7) | 52.9 (29.2-76.7) | |
| Advanced | 81.3 (71.7-90.8) | 54.7 (42.5-66.9) | 44.6 (32.3-57.0) | 42.4 (29.9-54.9) | .69* |
| Event-free survival | 77.8 (68.7-86.8) | 46.9 (36.0-57.8) | 40.4 (29.6-51.2) | 40.4 (29.6-51.2) | |
| Disease stage at HSCT | |||||
| Early | 82.4 (64.2-100.0) | 47.1 (23.3-70.8) | 47.1 (23.3-70.8) | 47.1 (23.3-70.8) | |
| Advanced | 76.6 (66.2-86.9) | 46.9 (34.6-59.1) | 38.6 (26.5-50.7) | 38.6 (26.5-50.7) | .66* |
| Relapse | 1.2 (0.2-8.7) | 14.8 (8.8-25.0) | 19.9 (12.8-30.9) | 21.7 (14.2-33.1) | |
| NRM | 17.3 (10.7-27.8) | 30.9 (22.3-42.8) | 33.6 (24.7-45.7) | 33.6 (24.7-45.7) |
| . | Day 100 . | 1 year . | 3 years . | 5 years . | P . |
|---|---|---|---|---|---|
| Overall survival | 81.5 (73.0-89.9) | 54.3 (43.5-65.2) | 46.5 (35.5-57.4) | 44.8 (33.7-55.8) | |
| Disease stage at HSCT | |||||
| Early | 82.4 (64.2-100.0) | 52.9 (29.2-76.7) | 52.9 (29.2-76.7) | 52.9 (29.2-76.7) | |
| Advanced | 81.3 (71.7-90.8) | 54.7 (42.5-66.9) | 44.6 (32.3-57.0) | 42.4 (29.9-54.9) | .69* |
| Event-free survival | 77.8 (68.7-86.8) | 46.9 (36.0-57.8) | 40.4 (29.6-51.2) | 40.4 (29.6-51.2) | |
| Disease stage at HSCT | |||||
| Early | 82.4 (64.2-100.0) | 47.1 (23.3-70.8) | 47.1 (23.3-70.8) | 47.1 (23.3-70.8) | |
| Advanced | 76.6 (66.2-86.9) | 46.9 (34.6-59.1) | 38.6 (26.5-50.7) | 38.6 (26.5-50.7) | .66* |
| Relapse | 1.2 (0.2-8.7) | 14.8 (8.8-25.0) | 19.9 (12.8-30.9) | 21.7 (14.2-33.1) | |
| NRM | 17.3 (10.7-27.8) | 30.9 (22.3-42.8) | 33.6 (24.7-45.7) | 33.6 (24.7-45.7) |
Data are percentages (ranges).
CI indicates 95% confidence interval.
Univariate analysis (Cox proportional hazards regression models).